✦ LIBER ✦

Fatal amebic colitis after high-dose dexamethasone therapy for newly diagnosed multiple myeloma

✍ Scribed by Chiharu I. Kobayashi; Go Yamamoto; Akimasa Hayashi; Satoshi Ota; Yoichi Imai; Masashi Fukayama; Mineo Kurokawa

Book ID: 105989628
Publisher: Springer
Year: 2010
Tongue: English
Weight: 190 KB
Volume: 90
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-010-0984-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination therapy with interferon-dexa

Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma

✍ Meletios A. Dimopoulos; Donna Weber; Kay B. Delasalle; Raymond Alexanian 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 392 KB 👁 1 views

Long-term follow-up after high-dose ther

Long-term follow-up after high-dose therapy for high-risk multiple myeloma

✍ Barlogie, B; Jagannath, S; Naucke, S; Mattox, S; Bracy, D; Crowley, J; Tricot, G 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 63 KB

A Phase II trial of pegylated liposomal

A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients

✍ Mohamad A. Hussein; Laura Wood; Eric Hsi; Gordan Srkalovic; MaryAnn Karam; Paul 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views

## Abstract ## BACKGROUND Patients with multiple myeloma (MM) have increased bone marrow angiogenesis, a low plasma cell labeling index, and multidrug resistance (the primary cause of chemotherapy failure). MM patients receiving the vincristine, doxorubicin, and dexamethasone (VAD) regimen develop

Impact of previous high-dose therapy on

Impact of previous high-dose therapy on outcome after allografting for multiple myeloma

✍ Kulkarni, S; Powles, R L; Treleaven, J G; Singhal, S; Saso, R; Horton, C; Killic 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 53 KB

Cyclophosphamide, bortezomib and dexamet

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

✍ Reeder, C B; Reece, D E; Kukreti, V; Chen, C; Trudel, S; Hentz, J; Noble, B; Pir 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 141 KB

Induction therapy with vincristine, adri

Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma

✍ Lokhorst, H M; Sonneveld, P; Cornelissen, J J; Joosten, P; van Marwijk Kooy, M; 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 66 KB